Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Equity Bottom-Up

<p><strong>Rexulti</strong> (brexpiprazole) is the next generation atypical antipsychotic, co-developed with Lundbeck as a successor to Abilify (aripiprazole). It is a serotonin-dopamine activity modulator (SDAM) that elicits greater action on the 5-HT1A and 5-HT2A receptors and less effect on D2 receptors compared to other antipsychotics. Rexulti received USFDA approval in Jul’15 as a monotherapy for the treatment of schizophrenia and as an adjunct therapy for major depressive disorder (MDD) and was launched a…</p>

Rexulti (brexpiprazole) is the next generation atypical antipsychotic, co-developed with Lundbeck as a successor to Abilify (aripiprazole). It is a serotonin-dopamine activity modulator (SDAM) that elicits greater action on the 5-HT1A and 5-HT2A receptors and less effect on D2 receptors compared to other antipsychotics. Rexulti received USFDA approval in Jul’15 as a monotherapy for the treatment of schizophrenia and as an adjunct therapy for major depressive disorder (MDD) and was launched a…

レキサルティ（ブレクスピプラゾール） - セロトニン・ドーパミン活性調節薬

Otsuka Holdings

レキサルティ（ブレクスピプラゾール） - セロトニン・ドーパミン活性調節薬